Compass Pathways to report Q2, first-half results, host conference callPUBT·1 day ago, 05:31 AMCMPS+6.15%
Industrial Mega-Deals and Retail Restructurings Highlight Divergent 2026 PathsGlobal Report·Jul 21 at 04:13 AMNAKA+15.65%LRLCY+2.23%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN0.00%CRSP+1.68%
Navigating the 2026 Economy: How AI and Resource Scarcity Are Rewiring Corporate StrategyGlobal Report·Jul 15 at 04:13 AMHAS-0.67%EH+4.86%
9 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 9 at 12:35 PMCAPR-36.23%LLY-4.55%
Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 LaunchTip Ranks·Jul 7 at 02:45 PMCMPS+6.15%
4 stocks to watch on Tuesday: CMPS, CRM, SNPS, ADSKbusinessinsider·Jul 7 at 08:15 AMADSK-4.19%SNPS-0.36%
Compass Pathways says Phase 3 COMP006 study shows COMP360 psilocybin maintains benefit through week 26 in TRDPUBT·Jul 7 at 05:30 AMCMPS+6.15%
Compass Pathways publishes investor deck on COMP360 psilocybin therapy for treatment-resistant depression approval pathPUBT·Jul 7 at 07:08 AMCMPS+6.15%
Compass gains on new late-stage trial data for psychedelic therapy in depressionbusinessinsider·Jul 7 at 06:30 AMCMPS+6.15%
